{"pmid":32350860,"title":"Dose rationale for favipiravir use in patients infected with SARS-CoV-2.","text":["Dose rationale for favipiravir use in patients infected with SARS-CoV-2.","We read with a great interest the paper by Du et Chen suggesting dosing regimen of favipiravir in COVID-19(1) . We would like to complement their observations with our PK/PD experience of favipiravir against Ebola virus (EBOV). The drug EC50 against EBOV and SARS-CoV-2 are 10-60 microg/ml and 9.4 microg/ml(4) , respectively. However results obtained by our working group suggest a higher value of EC50 , in the range 40-80 microg/ml (X. de Lamballerie & F. Touret, unpublished results). We therefore use the conservative assumption that the drug EC50 against SARS-CoV-2 is in the same range as against EBOV.","Clin Pharmacol Ther","Eloy, Philippine","Solas, Caroline","Touret, Franck","Mentre, France","Malvy, Denis","de Lamballerie, Xavier","Guedj, Jeremie","32350860"],"abstract":["We read with a great interest the paper by Du et Chen suggesting dosing regimen of favipiravir in COVID-19(1) . We would like to complement their observations with our PK/PD experience of favipiravir against Ebola virus (EBOV). The drug EC50 against EBOV and SARS-CoV-2 are 10-60 microg/ml and 9.4 microg/ml(4) , respectively. However results obtained by our working group suggest a higher value of EC50 , in the range 40-80 microg/ml (X. de Lamballerie & F. Touret, unpublished results). We therefore use the conservative assumption that the drug EC50 against SARS-CoV-2 is in the same range as against EBOV."],"journal":"Clin Pharmacol Ther","authors":["Eloy, Philippine","Solas, Caroline","Touret, Franck","Mentre, France","Malvy, Denis","de Lamballerie, Xavier","Guedj, Jeremie"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32350860","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/cpt.1877","keywords":["covid","antiviral drugs","favipiravir","pharmacokinetics"],"e_drugs":["favipiravir"],"topics":["Treatment"],"weight":1,"_version_":1666138495693881344,"score":9.490897,"similar":[{"pmid":32353191,"title":"Response to \"Dose rationale for favipiravir use in patients infected with SARS-CoV-2\".","text":["Response to \"Dose rationale for favipiravir use in patients infected with SARS-CoV-2\".","We appreciate the letter by Eloy P., et al for their comments and complement regarding our review(1-2) . Two independent in vitro studies indicated that favipiravir (T-705) inhibited SARS-CoV-2 replication in Vero E6 cells with EC50 values of 61.88 muM (9.4 mug/mL)(3) and >100 muM (15.7 mug/mL)(4) , respectively. Data from the authors' group suggests an EC50 value in the range 40-80 microg/mL (X. de Lamballerie & F. Touret, unpublished results). I agree with the authors' assumption that favipiravir shows similar EC50 against SARS-CoV-2 and EBOV. As favipiravir is a prodrug that requires metabolic activation through ribosylation and phosphorylation in the host cells to form its triphosphate form (favipiravir-RTP), we think that variation in favipiravir activation by the cultured cells may, at least partially, contribute to the difference in the in vitro EC50 among studies.","Clin Pharmacol Ther","Du, Yin-Xiao","Chen, Xiao-Ping","32353191"],"abstract":["We appreciate the letter by Eloy P., et al for their comments and complement regarding our review(1-2) . Two independent in vitro studies indicated that favipiravir (T-705) inhibited SARS-CoV-2 replication in Vero E6 cells with EC50 values of 61.88 muM (9.4 mug/mL)(3) and >100 muM (15.7 mug/mL)(4) , respectively. Data from the authors' group suggests an EC50 value in the range 40-80 microg/mL (X. de Lamballerie & F. Touret, unpublished results). I agree with the authors' assumption that favipiravir shows similar EC50 against SARS-CoV-2 and EBOV. As favipiravir is a prodrug that requires metabolic activation through ribosylation and phosphorylation in the host cells to form its triphosphate form (favipiravir-RTP), we think that variation in favipiravir activation by the cultured cells may, at least partially, contribute to the difference in the in vitro EC50 among studies."],"journal":"Clin Pharmacol Ther","authors":["Du, Yin-Xiao","Chen, Xiao-Ping"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32353191","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/cpt.1878","keywords":["covid-19","favipiravir","pharmacokinetics"],"e_drugs":["triphosphoric acid","favipiravir"],"weight":0,"_version_":1666138495750504448,"score":938.048},{"pmid":32475019,"title":"Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.","text":["Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.","Since December 2019, a novel coronavirus (SARS-CoV-2) infection has been rapidly spreading worldwide and causing the respiratory illness, coronavirus disease 2019 (COVID-19). The anti-retroviral drug favipiravir (FPV) has been experimentally used for COVID-19 treatment since March 2020 in Japan. However, the pharmacokinetics of FPV in critically ill patients is unknown. We measured the serum concentration of FPV using high-performance liquid chromatography in patients with severe COVID-19 who were admitted to the intensive care unit and placed on mechanical ventilation. The patients were administered 1600 mg of FPV twice daily on Day 1, followed by 600 mg twice daily from Day 2 to Day 5 (or more if needed). Suspensions of FPV tablets were administered through a nasogastric tube. Seven patients were enrolled in this study. Forty-nine blood samples were obtained from the eligible patients to evaluate FPV concentration. The FPV trough (after 8-12 h) concentrations of most samples were lower than the lower limit of quantification (1 microg/mL) and EC50 (9.7 microg/mL) against SARS-CoV-2 previously tested in vitro. FPV trough concentration in critically ill patients was much lower than that of healthy subjects in a previous clinical trial, which is a cause for great concern. Further study is required to determine the optimal strategy for treatment of patients with severe COVID-19.","Clin Transl Sci","Irie, Kei","Nakagawa, Atsushi","Fujita, Hirotoshi","Tamura, Ryo","Eto, Masaaki","Ikesue, Hiroaki","Muroi, Nobuyuki","Tomii, Keisuke","Hashida, Tohru","32475019"],"abstract":["Since December 2019, a novel coronavirus (SARS-CoV-2) infection has been rapidly spreading worldwide and causing the respiratory illness, coronavirus disease 2019 (COVID-19). The anti-retroviral drug favipiravir (FPV) has been experimentally used for COVID-19 treatment since March 2020 in Japan. However, the pharmacokinetics of FPV in critically ill patients is unknown. We measured the serum concentration of FPV using high-performance liquid chromatography in patients with severe COVID-19 who were admitted to the intensive care unit and placed on mechanical ventilation. The patients were administered 1600 mg of FPV twice daily on Day 1, followed by 600 mg twice daily from Day 2 to Day 5 (or more if needed). Suspensions of FPV tablets were administered through a nasogastric tube. Seven patients were enrolled in this study. Forty-nine blood samples were obtained from the eligible patients to evaluate FPV concentration. The FPV trough (after 8-12 h) concentrations of most samples were lower than the lower limit of quantification (1 microg/mL) and EC50 (9.7 microg/mL) against SARS-CoV-2 previously tested in vitro. FPV trough concentration in critically ill patients was much lower than that of healthy subjects in a previous clinical trial, which is a cause for great concern. Further study is required to determine the optimal strategy for treatment of patients with severe COVID-19."],"journal":"Clin Transl Sci","authors":["Irie, Kei","Nakagawa, Atsushi","Fujita, Hirotoshi","Tamura, Ryo","Eto, Masaaki","Ikesue, Hiroaki","Muroi, Nobuyuki","Tomii, Keisuke","Hashida, Tohru"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32475019","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/cts.12827","keywords":["covid-19","favipiravir","sars-cov-2"],"locations":["Japan","optimal"],"countries":["Japan"],"countries_codes":["JPN|Japan"],"topics":["Treatment"],"weight":1,"_version_":1668341932632309761,"score":372.9637},{"pmid":32418793,"title":"An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design.","text":["An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design.","The 2013-2016 West Africa EBOV epidemic was the biggest EBOV outbreak to date. An analysis of virus-specific CD8+ T-cell immunity in 30 survivors showed that 26 of those individuals had a CD8+ response to at least one EBOV protein. The dominant response (25/26 subjects) was specific to the EBOV nucleocapsid protein (NP). It has been suggested that epitopes on the EBOV NP could form an important part of an effective T-cell vaccine for Ebola Zaire. We show that a 9-amino-acid peptide NP44-52 (YQVNNLEEI) located in a conserved region of EBOV NP provides protection against morbidity and mortality after mouse adapted EBOV challenge. A single vaccination in a C57BL/6 mouse using an adjuvanted microsphere peptide vaccine formulation containing NP44-52 is enough to confer immunity in mice. Our work suggests that a peptide vaccine based on CD8+ T-cell immunity in EBOV survivors is conceptually sound and feasible. Nucleocapsid proteins within SARS-CoV-2 contain multiple Class I epitopes with predicted HLA restrictions consistent with broad population coverage. A similar approach to a CTL vaccine design may be possible for that virus.","Vaccine","Herst, C V","Burkholz, S","Sidney, J","Sette, A","Harris, P E","Massey, S","Brasel, T","Cunha-Neto, E","Rosa, D S","Chao, W C H","Carback, R","Hodge, T","Wang, L","Ciotlos, S","Lloyd, P","Rubsamen, R","32418793"],"abstract":["The 2013-2016 West Africa EBOV epidemic was the biggest EBOV outbreak to date. An analysis of virus-specific CD8+ T-cell immunity in 30 survivors showed that 26 of those individuals had a CD8+ response to at least one EBOV protein. The dominant response (25/26 subjects) was specific to the EBOV nucleocapsid protein (NP). It has been suggested that epitopes on the EBOV NP could form an important part of an effective T-cell vaccine for Ebola Zaire. We show that a 9-amino-acid peptide NP44-52 (YQVNNLEEI) located in a conserved region of EBOV NP provides protection against morbidity and mortality after mouse adapted EBOV challenge. A single vaccination in a C57BL/6 mouse using an adjuvanted microsphere peptide vaccine formulation containing NP44-52 is enough to confer immunity in mice. Our work suggests that a peptide vaccine based on CD8+ T-cell immunity in EBOV survivors is conceptually sound and feasible. Nucleocapsid proteins within SARS-CoV-2 contain multiple Class I epitopes with predicted HLA restrictions consistent with broad population coverage. A similar approach to a CTL vaccine design may be possible for that virus."],"journal":"Vaccine","authors":["Herst, C V","Burkholz, S","Sidney, J","Sette, A","Harris, P E","Massey, S","Brasel, T","Cunha-Neto, E","Rosa, D S","Chao, W C H","Carback, R","Hodge, T","Wang, L","Ciotlos, S","Lloyd, P","Rubsamen, R"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418793","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.vaccine.2020.04.034","keywords":["covid-19","ctl vaccine","controller","ebola zaire vaccine","flow focusing","sars-cov-2","yqvnnleei"],"locations":["West Africa"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667159284587167745,"score":268.67545},{"pmid":32344449,"title":"Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness.","text":["Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness.","Hydroxychloroquine is an antimalarial drug being tested as a potential treatment for the novel coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2( (SARS-CoV-2. Although the efficacy of hydroxychloroquine for COVID-19 remains uncertain, it may serve as a potential prophylactic agent especially in those at high risk, such as healthcare workers, household contacts of infected patients, and the immunocompromised. Our aim was to identify possible hydroxychloroquine dosing regimens through simulation in those at high risk of infections by optimizing exposures above the in vitro generated half maximal effective concentration (EC50 ) and to help guide researchers in dose-selection for COVID-19 prophylactic studies. To maintain weekly troughs above EC50 in >50% of subjects at steady state in a pre-exposure prophylaxis setting, an 800 mg loading dose followed by 400 mg twice or three times weekly is required. In an exposure driven post-exposure prophylaxis setting, 800 mg loading dose followed in 6 hours by 600 mg, then 600 mg daily for 4 more days achieved daily troughs above EC50 in >50% subjects. These doses are higher than recommended for malaria chemoprophylaxis, and clinical trials are needed to establish safety and efficacy.","Clin Pharmacol Ther","Al-Kofahi, Mahmoud","Jacobson, Pamala","Boulware, David R","Matas, Arthur","Kandaswamy, Raja","Jaber, Mutaz M","Rajasingham, Radha","Young, Jo-Anne H","Nicol, Melanie R","32344449"],"abstract":["Hydroxychloroquine is an antimalarial drug being tested as a potential treatment for the novel coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2( (SARS-CoV-2. Although the efficacy of hydroxychloroquine for COVID-19 remains uncertain, it may serve as a potential prophylactic agent especially in those at high risk, such as healthcare workers, household contacts of infected patients, and the immunocompromised. Our aim was to identify possible hydroxychloroquine dosing regimens through simulation in those at high risk of infections by optimizing exposures above the in vitro generated half maximal effective concentration (EC50 ) and to help guide researchers in dose-selection for COVID-19 prophylactic studies. To maintain weekly troughs above EC50 in >50% of subjects at steady state in a pre-exposure prophylaxis setting, an 800 mg loading dose followed by 400 mg twice or three times weekly is required. In an exposure driven post-exposure prophylaxis setting, 800 mg loading dose followed in 6 hours by 600 mg, then 600 mg daily for 4 more days achieved daily troughs above EC50 in >50% subjects. These doses are higher than recommended for malaria chemoprophylaxis, and clinical trials are needed to establish safety and efficacy."],"journal":"Clin Pharmacol Ther","authors":["Al-Kofahi, Mahmoud","Jacobson, Pamala","Boulware, David R","Matas, Arthur","Kandaswamy, Raja","Jaber, Mutaz M","Rajasingham, Radha","Young, Jo-Anne H","Nicol, Melanie R"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344449","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/cpt.1874","keywords":["covid-19","sars-cov-2","hydroxychloroquine","pharmacokinetics"],"e_drugs":["Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138495828099072,"score":261.1981},{"pmid":32401463,"title":"Favipiravir","text":["Favipiravir","Favipiravir is an investigational antiviral drug that is being tested for use against the novel coronavirus disease, COVID-19. No information is available on the use of favipiravir during breastfeeding or its excretion into breastmilk. Favipiravir is a small molecule that is about 60% protein bound in plasma, so it would be expected to appear in breastmilk and be absorbed by the infant, probably in small amounts. In clinical trials, favipiravir has been well tolerated, but has caused liver enzyme abnormalities, gastrointestinal symptoms, and serum uric acid elevations.[1-3] If favipiravir is used in a nursing mother, these parameters should be monitored in the breastfed infant.","Drugs and Lactation Database (LactMed)","32401463"],"abstract":["Favipiravir is an investigational antiviral drug that is being tested for use against the novel coronavirus disease, COVID-19. No information is available on the use of favipiravir during breastfeeding or its excretion into breastmilk. Favipiravir is a small molecule that is about 60% protein bound in plasma, so it would be expected to appear in breastmilk and be absorbed by the infant, probably in small amounts. In clinical trials, favipiravir has been well tolerated, but has caused liver enzyme abnormalities, gastrointestinal symptoms, and serum uric acid elevations.[1-3] If favipiravir is used in a nursing mother, these parameters should be monitored in the breastfed infant."],"journal":"Drugs and Lactation Database (LactMed)","date":"2020-05-14T11:01:00Z","year":2006,"_id":"32401463","source":"PubMed","week":"202020|May 11 - May 17","keywords":["favipiravir","avigan","6-fluoro-3-hydroxy-2-pyrazinecarboxamide","t 705","t-705","t705","unii-ew5gl2x7e0","5-fluoro-2-oxo-1h-pyrazine-3-carboxamide","2-pyrazinecarboxamide, 6-fluoro-3-hydroxy-"],"topics":["Treatment"],"weight":1,"_version_":1666714494907187200,"score":228.88838}]}